Biotech
-
Getty Images
GondolaBio gives new meaning to ‘sweat equity’ in rare R&D
Instead of investing cash, Children’s Tumor Foundation is offering its clinical expertise and scientific infrastructure in exchange for an equity stake in GondolaBio’s preclinical drug program.
By Alexandra Pecci • Nov. 10, 2026 -
Getty Images
Could new US rules on China biotech investments give Europe an edge?
Treasury’s proposed COINS Act regulations could complicate U.S.-backed NewCos, potentially giving European drugmakers more room to pursue Chinese assets.
By Kelly Bilodeau • Nov. 9, 2026 -
Explore the Trendline➔
Getty Images
TrendlineTech for Clinical Trials
Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.
By PharmaVoice staff -
Permission granted by Cytiva
Sponsored by CytivaHow can we build trust in model-driven manufacturing?
Predict, optimize and act sooner with model-driven bioprocessing.
By Martin Ball, Senior Product Marketing Manager, Automation and Digital, Cytiva • Nov. 9, 2026 -
Andrew Harnik via Getty Images
The end of MAHA?; Inovio’s big FDA win
American voters turned their noses up at MAHA-aligned candidates this week; Inovio won a breakthrough nod for a DNA-based therapy.
By PharmaVoice Staff • Nov. 6, 2026 -
Jon Cherry via Getty Images
Ramaswamy’s biotech baggage haunted his political run
A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.
By Sy Mukherjee • Nov. 5, 2026 -
Sarah Silbiger via Getty Images
A push for speedier drug approvals doesn’t promise smooth market sailing
Investors and payers sometimes balk at drugs approved on an accelerated pathway. Here’s how pharma can de-risk these medications while they’re still in development.
By Alexandra Pecci • Nov. 4, 2026 -
Getty Images
Anthropic’s historic IPO; Akeso’s big clinical showing
Anthropic is setting the stage for the largest IPO in history and Akeso has been touting its latest positive results for its buzzy bispecific.
By PharmaVoice Staff • Oct. 30, 2026 -
Getty Images
What 3 multibillion dollar biotechs still have to prove
Summit, Abivax and Viking have lofty valuations but no FDA-approved products. Each faces a different test of its clinical promise and commercial potential.
By Meagan Parrish • Oct. 27, 2026 -
Permission granted by Courtesy of Immunic Therapeutics
MS has plenty of drugs. This Ocrevus veteran sees what’s missing.
After helping launch a blockbuster Roche and Genentech therapy, Erik Lundgren is betting Immunic's experimental drug can address persistent gaps in MS care, with pivotal trial results approaching.
By Alexandra Pecci • Oct. 26, 2026 -
Permission granted by Cytiva
Sponsored by CytivaBioprocessing observability: why real-time monitoring matters
What is bioprocess observability? See how real-time monitoring improves process control.
By Martin Ball, Senior product marketing manager, automation and digital • Oct. 26, 2026 -
Getty Images
Drug discovery is speeding up. But clinical trials are buckling under their own weight.
A growing pipeline is colliding with tougher recruitment, more demanding protocols and trial operations struggling to keep pace — and AI alone can’t fix it.
By Sy Mukherjee • Oct. 22, 2026 -
Pete Marovich via Getty Images
A CEO, an ex-CDC director and an ex-FDA commissioner walk into a biotech…
Dr. Robert Redfield and Dr. Stephen Hahn came aboard Turn Therapeutics this year to help the clinical-stage company develop a platform that could one day change how vaccines are delivered.
By Kelly Bilodeau • Oct. 21, 2026 -
Getty Images
Biotech is booming — and startups are still dying
Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs to the brink.
By Meagan Parrish • Oct. 19, 2026 -
Getty Images
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
New types of bispecifics, ADCs and CAR-Ts are still proving themselves in the clinic — pharma’s betting billions anyway.
By Sy Mukherjee • Oct. 15, 2026 -
Getty Images
Q&A // Biotech SpotlightA new startup takes aim at a suspected culprit in autoimmune disease
Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune conditions: diseased T cells.
By Kelly Bilodeau • Oct. 14, 2026 -
Getty Images
Top pharma industry conferences in 2027
Where pharma and biotech leaders will converge to network, share ideas and potentially strike deals.
By Meagan Parrish • Oct. 6, 2026 -
Getty Images
The next frontier in obesity drugs: lasting weight loss
Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.
By Kelly Bilodeau • Oct. 6, 2026 -
Getty Images
Roche’s AI lab; Biohaven’s pivotal pause
Roche announced it's building autonomous AI-powered labs; how a clinical hold on an epilepsy trial could impact Biohaven
By PharmaVoice Staff • Oct. 2, 2026 -
Getty Images
Are psychedelics as effective as trials suggest?
Patients often know when they’ve received a psychedelic, potentially distorting trial results. Researchers are testing new ways to make those studies more reliable.
By Kelly Bilodeau • Oct. 1, 2026 -
Getty Images
Beam sues 2 biotechs, alleging theft of base editing trade secrets
Beam claimed a former scientist stole confidential information and quietly spun up a rival rare disease treatment at YolTech Therapeutics. Serapha Bio, which licensed that therapy, denies the charges.
By Gwendolyn Wu • Sept. 30, 2026 -
Getty Images
Epilepsy R&D is breaking out of its old playbook
Genetic medicines and more selective small molecules are finally pushing the field toward new mechanisms — and potentially disease-modifying treatments.
By Kelly Bilodeau • Sept. 29, 2026 -
Getty Images
Nimbus used AI to help develop Takeda’s $4B psoriasis bet. Here’s where it’s taking the tech next
Nimbus Therapeutics’ head of R&D dishes on what’s next in AI-enabled drug discovery, years after Takeda completed its zasocitinib acquisition.
By Alexandra Pecci • Sept. 25, 2026 -
Getty Images
Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry
Some of the biggest news and trends captured in PharmaVoice’s newsletter this week. Sign up here to receive the newsletter daily. Another big AI haul Investors are still lining up to back AI drug developers before their candidates reach human trials. Basecamp Research...
By PharmaVoice Staff • Sept. 25, 2026 -
Getty Images
A norovirus breakthrough?; another women’s healthtech haul
Yale researchers untangled norovirus RNA and Evvy just pulled in $40 million for precision medicine in women's health.
By PharmaVoice Staff • Sept. 18, 2026 -
Getty Images
A dark horse in the orexin race?
As the orexin competition heats up in the neuroscience space, Harmony Biosciences is developing an early-stage asset it believes could have an edge over rivals.
By Meagan Parrish • Sept. 18, 2026
